Who Supplies Dapagliflozin to India from SPAIN

Importing finished pharmaceutical formulations containing Dapagliflozin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, as defined under Rule 122E, prior approval is necessary before importation. Applications for registration and import licenses must be submitted to the Drugs Controller General (I) at CDSCO. The registration process involves submitting detailed documentation, including the drug's composition, manufacturing process, and stability data. The timeline for obtaining import drug registration varies but typically ranges from several months to a year, depending on the completeness of the application and regulatory review processes. Specific requirements for Dapagliflozin formulations under HS Code 30049099 include providing evidence of safety, efficacy, and quality, along with compliance with Indian pharmacopoeia standards.

Imported finished pharmaceutical formulations containing Dapagliflozin must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under India's climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported drugs. If a batch fails quality testing, it may be rejected, leading to potential delays and financial losses for the importer.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Spain have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Spanish pharmaceutical products.

India imports finished Dapagliflozin formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms or strengths may be required to meet patient needs, which are not produced by Indian manufacturers. While India has a growing domestic pharmaceutical industry, certain specialized formulations still rely on imports to fulfill market demand. The market size for Dapagliflozin in India is substantial, with a significant number of patients requiring this medication for managing type 2 diabetes.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Goods and Services Tax (GST) at 12% is applicable on the imported value. There are no exemptions or preferential rates for imports from Spain. Therefore, the total landed duty percentage is 32% (20% duty + 12% GST).

India sources finished Dapagliflozin formulations from Spain due to the availability of patented formulations and specialized dosage forms that are not produced domestically. Spanish manufacturers are known for high-quality standards and compliance with international regulatory requirements, which enhances the reliability of their products. While other countries like China, Germany, and the United States also supply Dapagliflozin formulations, Spain's competitive advantage lies in its established trade relations with India and the quality assurance of its pharmaceutical products.

India imports finished Dapagliflozin formulations from Spain due to the availability of patented formulations and specialized dosage forms not produced domestically. Spanish manufacturers offer high-quality products that meet international standards, ensuring efficacy and safety. The established trade relations and mutual recognition of Good Manufacturing Practices (GMP) between India and Spain further facilitate this sourcing.

Compared to other origins like China, Germany, and the United States, Spain offers a competitive advantage in terms of product quality and regulatory compliance. Spanish pharmaceutical products are known for their adherence to stringent quality standards, which is crucial for the importation of finished formulations. While other countries may offer lower prices, Spain's reputation for quality and reliability makes it a preferred source for importing Dapagliflozin formulations.

Importing finished pharmaceutical formulations from Spain involves certain risks, including potential regulatory changes, currency fluctuations, and shipping disruptions. To mitigate these risks, Indian importers should maintain dual sourcing strategies, establish robust inventory management practices, and stay informed about regulatory updates in both countries. Regular audits and quality checks can also help ensure product quality and compliance with Indian standards.

1. 1Dual Sourcing: Engage with multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and avoid overstocking.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities, to ensure compliance with quality standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade (DGFT).
2. 2CDSCO Registration: Register the drug and manufacturing site with CDSCO.
3. 3Form 40/41: Submit the application for import registration using the appropriate forms.
4. 4Drug Import License: Obtain